Stocks›Healthcare›NEOG

NEOG

Neogen Corporation
NasdaqResearch view

Neogen Corporation operates in the In Vitro & In Vivo Diagnostic Substances industry.

$11.96−8.07%
Oct 6 close · 1D EOD · Databento
HealthcareIn Vitro & In Vivo Diagnostic SubstancesMid-capSEC EDGAR FY 2026-05-31

The numbers · FY2026, filed

SEC EDGAR
Market cap$2.6B
Revenue$870.4M−2.70%
Net income$-7.9M
EPS, diluted$-0.04+99.20%
Gross margin46.9%
Operating margin-2.5%
All filed figures

Snapshot

SEC EDGAR · FY 2026-05-31
SectorHealthcare
Market Cap$2.6B
Enterprise Value$3.3B
Income$-7.9M
Sales$870.4M
Book/sh$9.60
Cash/sh$0.85
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio2.91
Current Ratio3.82
Debt/Eq0.38
EPS (ttm)$-0.04
EPS this Y99.2%
EPS past 3/5Y—
Sales past 3/5Y1.9%
EPS Y/Y TTM99.2%
Sales Y/Y TTM-2.7%
Shs Outstand218.06M
ROA-0.2%
ROE-0.4%
ROIC-0.7%
Gross Margin46.9%
Oper. Margin-2.5%
Profit Margin-0.9%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$527.2M
FY22
$822.4M
FY23
$924.2M
FY24
$894.7M
FY25
$870.4M
FY26

Operating leverage — margins

GrossOperatingNet
0%40%80%47%-2%-1%FY22FY23FY24FY25FY26
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it
USDFY2022FY2023FY2024FY2025FY2026

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.